Sunday, January 27, 2019
Multidisciplinary Treatment of Obesity Prior to in Vitro Fertilization: Impact on Global Reproductive Outcomes (PRO-FIV Study)
Brief description of study
The aim of the present study is to evaluate the impact of a multidisciplinary treatment of obesity prior to IVF on global reproductive outcomes and maternofetal metabolic and cardiovascular risk factors.
This is a randomized controlled trial in obese infertile women before starting an IVF cycle. The intervention is based on a structured multidisciplinary program in support groups, which includes diet, physical activity and psychological therapy. IVF will be started immediately after this therapy. Patients included in the control group will start an IVF cycle immediately after the randomization. The results of this study may allow the identification of patients who would benefit from obesity treatment, so as to establish appropriate preventive and therapeutic strategies and to reduce the maternal obesity impact in future generations.
Detailed Study Description
The aim of the present study is to evaluate the impact of a multidisciplinary treatment of obesity prior to IVF on global reproductive outcomes and maternofetal metabolic and cardiovascular risk factors.
This is a randomized controlled trial in obese infertile women (body mass index 30 kg/m2) before starting an IVF cycle. In the intervention group, the aim is a weight loss of at least 10% in a 16-week period of treatment based on a multidisciplinary approach and support groups, which includes diet, physical activity and psychological therapy. IVF will be started immediately after this period. Patients included in the control group will start an IVF cycle immediately after the randomization. The results of this study may allow the identification of patients who would benefit from obesity treatment, so as to establish appropriate preventive and therapeutic strategies and to reduce the maternal obesity impact in future generations.
Subscribe to:
Post Comments (Atom)
Study Shows MVT-602 Be a Novel Fertility-Improving Drug
MVT-602 is a Novel Fertility-Improving Drug FERTILITY in women with reproductive health problems can be improved using a new drug accordin...
-
ABSTRACT INTRODUCTION: During sexual stimulation, some women report the discharge of a noticeable amount of fluid from the urethra, a...
-
The predictive ability of a biomarker risk score beyond established risk factors may help identify women at risk of developing gestational d...
-
As devices become smarter and smarter and improve patient outcomes, they also pose challenges for patient and clinician education. While ...
No comments:
Post a Comment